All 54 infants were followed up for

All 54 infants were followed up for more than 12 months, 11 were followed up for more than 2 years, and one was followed up for more than 3 years. None of the infants had abnormal hearing, congenital phenylketonuria, hypothyroidism, congenital heart disease, or congenital hip dislocation. Three infants in the early-pregnancy treatment group had abnormalities postpartum: one infant with ankyloglossia without delayed language development whose parents planned to arrange surgery when he was 2 years old and one infant with a 3 × 3-cm cutaneous hemangioma on the right foot after 4–5 months of topical therapy that disappeared when the infant was 7 months old. Another infant with vaginal canal leak underwent successful surgery when the infant was 1 month old. Other infants showed no signs of abnormal congenital dysplasia. Thus, the abnormality rate of all infants in this study was 5.56% (3/54). There were no significant differences in the abnormality rates between the children observed in this study and the controls in 2010 (72/2747, Chi-square = 1.569, p = 0.403) or 2011 (50/2567, Chi-square = 3.46, p = 0.090).

The most common adverse events for infants younger than 6 weeks old were eczema (14/54, 25.92%) and hypocalcemia (11/54, 20.37%). The most common adverse events for infants younger than 12 months old were respiratory tract infection (7/30, 23.33%), diarrhea (5/54, 9.25%), and eczema (4/54, 7.41%). Other adverse events in infants included nasal obstruction, neonatal pneumonia, myocardial damage, newborn infection, and inguinal hernia. One case in the late-pregnancy treatment group had language retardation; this patient had delayed language abilities without a nervous disorder.